Tom Price, Health and Human Services
NEW! "Tom Price, Dr Personal Enrichment" and "Tom Price: a Bigger Problem than Betsy DeVos."
Trump's HHS nominee supports privatizing Medicare, says Politico, meaning that "seniors would receive fixed dollar amounts to buy coverage — an approach that Democrats lambaste as a voucher system that would gut a 50-year-old social contract and shift a growing share of health care costs onto seniors. Republicans argue the changes are needed to keep Medicare from going bankrupt. Trump’s transition spokesman did not return calls Tuesday about whether the president-elect now shares his nominee’s views on Medicare."
Senator Patty Murray questioned nominee Price, at his hearing, on GOP efforts to rush into dismantling health care.
Trump's HHS nominee supports privatizing Medicare, says Politico, meaning that "seniors would receive fixed dollar amounts to buy coverage — an approach that Democrats lambaste as a voucher system that would gut a 50-year-old social contract and shift a growing share of health care costs onto seniors. Republicans argue the changes are needed to keep Medicare from going bankrupt. Trump’s transition spokesman did not return calls Tuesday about whether the president-elect now shares his nominee’s views on Medicare."
Senator Patty Murray questioned nominee Price, at his hearing, on GOP efforts to rush into dismantling health care.
Looks like Price also indulged in insider trading while in Congress. An article in The Hill says Price "purchased shares in a medical device manufacturer and then introduced legislation that would benefit the company, according to a CNN report Monday.
"Rep. Tom Price (R-Ga.) in March
bought between $1,001 and $15,000 worth of shares in Zimmer Biomet. Days later,
he introduced the HIP Act to delay a Centers for Medicare and Medicaid Services
regulation that industry analysts said would have significantly hurt that
company financially, according to CNN.
"Zimmer Biomet, a leading
manufacturer of hip and knee replacement, was reportedly one of two companies
that would have been hit hardest by the CMS regulation directly affecting
payments for those procedures."
